New Zealand is still far behind Australia and the United Kingdom when it comes to funding of melanoma drugs, according to a new study.
Earlier this month, Pharmac announced it would fully fund Keytruda from 1 September.
But last week, a woman with stage-four melanoma told the Health Select Committee Pharmac could have saved hundreds of lives if it had moved faster to fund Keytruda and Opdivo.
The paper - published by the Medical Journal - said although more funding was now available, the way the funding decisions were made was still a problem.
One of its authors, Rosalie Stephens, a Melanoma New Zealand trustee, said there had been so much suffering and death, because of the time it took for basic drugs to be subsidised.